Financials in USD. Standardized financial statements.
A compact view of how KalVista Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $73.62M | $0 | $0 | $0 | $0 | $0 | $12.69M | $16.13M | $8.39M | $1.50M |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | -21.3% | +92.1% | +458.1% | 0.0% |
| Cost of Revenue? | $6.08M | $0 | $86.17M | $0 | $0 | $41.29M | $40.19M | $35,021 | $18,237 | $12,666 |
| Gross Profit? | $67.54M | $0 | -$86.17M | $0 | $0 | -$41.29M | -$27.50M | $16.09M | $8.38M | $1.49M |
| Gross Margin? | +91.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -216.7% | +99.8% | +99.8% | +99.2% |
| Operating Expenses? | $239.38M | $188.00M | $54.28M | $110.87M | $96.61M | $16.64M | $13.03M | $45.95M | $27.10M | $23.84M |
| Operating Income? | -$171.84M | -$188.00M | -$140.44M | -$110.87M | -$96.61M | -$57.92M | -$40.53M | -$29.82M | -$18.70M | -$22.34M |
| EBITDA? | -$170.38M | -$173.33M | -$134.28M | -$94.37M | -$80.75M | -$57.39M | -$40.02M | -$29.44M | -$18.52M | -$22.30M |
| Income Before Tax | -$171.42M | -$180.05M | -$135.10M | -$92.91M | -$82.34M | -$46.24M | -$28.99M | -$20.69M | -$15.80M | -$18.60M |
| Income Tax Expense | -$7.13M | $3.39M | -$8.45M | $0 | $0 | $0 | $124,000 | $124,000 | $0 | $0 |
| Net Income? | -$164.29M | -$183.44M | -$126.64M | -$92.91M | -$82.34M | -$46.24M | -$29.12M | -$20.82M | -$15.80M | -$18.60M |
| EPS? | $-3.23 | $-3.69 | $-3.44 | $-3.33 | $-3.36 | $-2.33 | $-1.64 | $-1.38 | $-1.53 | $-1.92 |
| Diluted EPS? | $-3.23 | $-3.69 | $-3.44 | $-3.33 | $-3.36 | $-2.33 | $-1.64 | $-1.38 | $-1.53 | $-1.92 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality